

ReNeuron

17 December 2025

ReNeuron Group plc
("ReNeuron" or the "Company")

Result of AGM

ReNeuron Group, a biotechnology company harnessing the natural biology of exosomes to develop next-generation drug delivery systems, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The results of the AGM are detailed below:

		For	% voted in favour	Against	% voted against	Withheld
Special resolutions						
1	Change of Name	12,837,947	97.23	365,640	2.77	86,549
2	Articles of Association	12,813,019	97.15	375,805	2.85	101,312
3	Allot Equity Securities	12,782,284	96.76	427,624	3.24	80,228
4	Allot Ordinary Shares	6,752,977	88.64	865,280	11.36	5,671,879
5	Pre-Emption Rights	7,104,855	93.13	524,486	6.87	5,660,795
6	Conflicts of Interest	12,402,433	94.42	732,734	5.58	154,969
Ordinary resolutions						
7	Reports & Accounts 1	13,043,266	99.21	104,086	0.79	142,784
8	Reports & Accounts 2	13,043,445	99.21	103,970	0.79	142,721
9	Re-appoint Auditors	12,969,412	99.01	129,132	0.99	191,592
10	Re-appoint Randolph Corteling	12,977,970	99.17	109,223	0.83	202,943
11	Re-appoints Iain Ross	12,354,917	94.78	679,586	5.22	255,363
12	Re-appoint Barabra Staehelin	12,675,484	97.24	359,352	2.76	255,300
13	Allot shares	12,675,656	97.00	392,222	3.00	222,258

To register to receive ongoing investor communications from ReNeuron please email: reneuron@walbrookpr.com

Enquiries:

ReNeuron Group plc

Via Walbrook PR

Iain Ross, Chairman

Randolph Corteling, Managing Director & Chief Scientific Officer

Walbrook PR (Media & Investor Relations)


Alice Woodings / Paul McManus

Tel: +44 (0)20 7933 8780 or reneuron@walbrookpr.com

Mob: +44 (0)7407 804 654 or Mob: +44 (0)7980 541 893

Information re. share ownership

The Company's shares are no longer publicly traded and the Directors have been unable to establish a cost-effective or efficient means for shareholders to establish a market value for these shares beyond nominal value (1 pence) or a mechanism to trade their shares privately.



If shareholders do wish to dispose of their shares at nominal value then please contact the Company via Walbrook PR.

